Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

NCT05903833 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Vulvar Cancer
Persistent Vulvar Cancer
Metastatic Vulva Cancer
Locally Advanced Vulvar Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Lenvatinib

Sponsor

AGO Research GmbH